Details

Autor(en) / Beteiligte

• Pineda-Moncusí, Marta
• Servitja, Sonia
• Casamayor, Guillem
• Cos, Maria Lourdes
• Rial, Abora
• Rodriguez-Morera, Jaime
• Tusquets, Ignasi
• Diez-Perez, Adolfo
• Garcia-Giralt, Natalia
• Nogués, Xavier

Titel

Bone health evaluation one year after aromatase inhibitors completion

Ist Teil von

• Bone (New York, N.Y.), 2018-12, Vol.117, p.54-59

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2018

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• Breast cancer patients treated with aromatase inhibitors (AIs) experience increased bone loss during their treatment. However, there is little information about bone mineral density (BMD) after completing AI-treatment. The present study aimed to assess BMD changes one year after AI-therapy completion. Data were collected from 864 postmenopausal women treated with AI during 5 years (5y-AI group), or during 2–3 years after taking tamoxifen therapy (pTAM-AI group). Participants with osteoporosis were treated with oral bisphosphonates (BP). BMD changes in lumbar spine (LS), femoral neck (FN) and total hip (TH) between baseline, end of treatment, and at one year post-treatment were assessed using repeated-measures ANOVA. At the end of AI-treatment, 382 patients had available BMD values and 316 also had post-treatment BMD values. As expected, BMD levels were decreased at AI-completion in non-BP treated patients. After one year, LS BMD increased in both groups (5y-AI: +2.11% [95%CI: 1.55 to 2.68], p < 0.001; pTAM-AI: +1.00% [95%CI: 0.49 to 1.51], p < 0.001) compared with the end of AI-therapy, while values at FN and TH remained stable. On the other hand, BMD values of BP-treated patients were increased or maintained at the end of AI-treatment and also at post-treatment. At one year after AI-completion, FN and TH BMD remained reduced in non-BP treated women, while LS BMD was recovered in the 5y-AI group and partially recovered in the pTAM-AI group. BP treatment increased or maintained BMD values at the end of therapy and at one year post-treatment. •Bone mineral density (BMD) levels decrease during aromatase inhibitor (AI) therapy.•At one year after AI-completion, femoral neck and total hip BMD remained reduced.•At one year after AI-completion, lumbar spine BMD was recovered in patients treated with 5 years of AI.•Lumbar spine BMD was partially recovered at one year after AI-completion in AI-patients previously treated with tamoxifen.•Bisphosphonate treatment increased or maintained BMD values at the end of AI therapy and at one year post-treatment.